Fortress Biotech, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Fortress Biotech, Inc. (FBIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $11.60 million for the 12-month period ending 2014-12-31, per its 10-K filed 2017-03-16.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2017-03-16
- Fortress Biotech, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2014 was $11.60M, a 307692207.69% increase from fiscal 2013.
- Fortress Biotech, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2013 was $3.77, a 34.32% decline from fiscal 2012.
- Fortress Biotech, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2012 was $5.74.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|
| 2014-12-31 | $11.60M 10-K · filed 2017-03-16 |
| 2013-12-31 | $3.77 10-K · filed 2015-03-16 |
| 2012-12-31 | $5.74 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |